Lv1
48 积分 2024-11-24 加入
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
9天前
已完结
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
9天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
13天前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
14天前
已完结
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis
21天前
已完结
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors
22天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
27天前
已完结
No Overall Survival Benefit with Adding Chemotherapy to Immunotherapy in PD-L1 TPS ≥ 50% NSCLC: An Agent-Stratified Reassessment
30天前
已关闭
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
30天前
已完结
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
1个月前
已完结